MyStart Health vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
MyStart Health
Best for fastest compounded GLP-1 onboarding with a price lockStarting at $299/mo
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launchStarting at $149/mo
Side-by-Side Comparison
| Feature | MyStart Health | Ro |
|---|---|---|
| Overall Score | 7.7/10 | ✓7.9/10 |
| Starting Price | $299/mo | ✓$149/mo |
| Editorial Rating | 3.9 ★ /5 | ✓4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
MyStart Health
Pros
- ✓Price Lock Guarantee — base monthly rate ($299) doesn't increase even when your prescribed dose escalates
- ✓Fast onboarding: quoted 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- ✓24/7 access to the care team with unlimited clinician messaging included
- ✓LegitScript certified
- ✓Transparent Section 503A compounding disclosure on every landing page
Cons
- ✗Not BBB accredited — BBB rating of C+ with 10 complaints filed against the business (BBB file opened April 24, 2025), most involving shipping delays and customer service access issues in early 2026
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Oral tirzepatide referenced in marketing but FAQ clarifies injectable is 'currently more common' — no FDA-approved oral tirzepatide exists, and the November 2025 Chimicles class action against OpenLoop/Triad Rx over unapproved oral tirzepatide products is a cautionary data point for the category
- ✗Very recent company (incorporated May 21, 2024 per BBB) — limited operational track record
- ✗Pharmacy partners not publicly named — no independent way to verify 503A compliance
- ✗Clinical efficacy claims are based on a homepage survey of only 16 self-reporting customers
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Ro edges out MyStart Health with a higher overall score of 7.9/10 and is particularly strong for broadest GLP-1 formulary including Foundayo on day-one of launch. MyStart Health remains a solid alternative, especially if you're looking for fastest compounded GLP-1 onboarding with a price lock.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.